1Robertson JF, Erikstein B, Osborne KC, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer [ J ]. Clin Pharmacokinet, 2004, 43 ( 8 ) :529 - 538.
2Osborne CK, Coronado-Heinsohn EB, Hilsenbeek SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer [ J ]. J Natl Cancer Inst, 1995,87 ( 10 ) :746 - 750.
3Addo S,Yates RA,Laight A. A phase I trial to assess the pharmacology of the new oestrogen reeeptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers [ J ]. Br J Cancer, 2002,87 ( 12 ) : 1354 - 1359.
4Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study [J].J Clin Oncol, 2009,27 (27) : 4530 - 4535.
5Chia S, Gradishar W, Mauriae L', et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer : results from EFECT [ J]. J Clin Oncol,2008,26 (10) : 1664 - 1670.
6Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases:data from the EFECT trial [ J ]. Breast Cancer Res Treat,2009,117 ( 1 ) :69 - 75.
7Xu B, Jiang Z, Shao Z, et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer : results of a muhicentre, double-blind, randomised phase Ⅲ trial [J]. Cancer Chemother Pharmacol,2011, 67( 1 ) :223 -230.
8Valachis A, Mauri D, Polyzos NP, et al. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials [J].Crit Rev Oncol Hematol,2010,73 (3) :220 - 227.
9Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [ J ]. J Clin Onco1,2010,28 (30) :4594 - 4600.
10Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study ( FINDER1 ) [ J ]. Ann Oncol,2010,21 (12) :2342 -2347.
